




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Goldberg et al.	Examiner: To be assigned
Serial No: 10/050,686	Art Unit: 1646
Filed: January 16, 2002	
For: <i>Compositions and Methods for Treatment of Muscle Wasting</i>	Attorney Docket No. HMV-070.01

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

**CERTIFICATE OF FIRST CLASS MAILING**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: U. S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202, on May 20, 2002.

  
Daniel Murray

**PRELIMINARY AMENDMENT**

Dear Sir:

Prior to substantive examination of the above-referenced application, please amend the specification as follows.

**In the specification:**

Please replace the two paragraphs at page 4, lines 8-20, with the following two replacement paragraphs:

One aspect of the present invention relates to isolated and/or recombinant forms of a cell- or tissue-specific F-box proteins, and portions thereof. For instance, there is provided isolated and/or recombinant polypeptides having an amino acid sequence identical or homologous (e.g., at least 65, 75, 85 or 95%) to the amino acid sequence as set forth in Figure 5B (SEQ ID NO: 2). The cell- or tissue-specific F-box polypeptide can have an amino acid sequence encoded by a nucleic acid which hybridizes under stringent conditions to the nucleotide sequence set forth in Figure 5A (SEQ ID NO: 1).

In another embodiment, other isolated and/or recombinant cell- or tissue-specific F-box polypeptides are provided, e.g., having an amino acid sequence identical or homologous (e.g., at